



HAL
open science

Mn(II)-based MRI contrast agent candidate for vascular imaging

Ferenc K Kalman, Viktória Nagy, Balázs Váradi, Zoltán Garda, Enikő Molnár, György Trencsényi, János Kiss, Sandra Mème, William Mème, Eva Tóth, et al.

► **To cite this version:**

Ferenc K Kalman, Viktória Nagy, Balázs Váradi, Zoltán Garda, Enikő Molnár, et al.. Mn(II)-based MRI contrast agent candidate for vascular imaging. *Journal of Medicinal Chemistry*, 2020, 63 (11), pp.6057-6065. 10.1021/acs.jmedchem.0c00197 . hal-02996069

HAL Id: hal-02996069

<https://hal.science/hal-02996069>

Submitted on 16 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Mn(II)-based MRI contrast agent candidate for vascular imaging

Ferenc K. Kálmán,^{1,2} Viktória Nagy,¹ Balázs Váradi,¹ Zoltán Garda,¹ Enikő Molnár,¹ György Trencsényi,³ János Kiss,³ Sandra Mème,⁴ William Mème,⁴ Éva Tóth*,⁴ and Gyula Tircsó*,¹

¹ Department of Physical Chemistry, H-4032, Debrecen, Egyetem tér 1, Faculty of Science and Technology, University of Debrecen, Hungary

² Le Studium, Loire Valley Institute for Advanced Studies, 1 Rue Dupanloup, 45000 Orléans, France

³ Division of Nuclear Medicine, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, H-4032 Debrecen (Hungary)

⁴ Centre de Biophysique Moléculaire, CNRS-UPR 4301, Université d'Orléans, Rue Charles Sadron, CS 80054, 45071 Orléans, France

Supporting Information Placeholder

ABSTRACT: Toxicity concerns related to Gd(III)-based MRI agents prompted an intensive research towards their replacement by complexes of essential Mn(II) ion. Here, we report a macrocyclic chelate, [Mn(PC2A-BP)], which possesses high thermodynamic stability and kinetic inertness as well as remarkable relaxivity ($r_{1p} = 23.5 \text{ mM}^{-1}\text{s}^{-1}$, 20 MHz, 37 °C) in the presence of human serum albumin allowing a significant MRI signal intensity increase in the vasculature even at low dose (25 $\mu\text{mol/kg}$) of the complex.

Introduction

Magnetic Resonance Imaging (MRI) has been used in medical diagnosis for its excellent soft tissue imaging capability for decades now. To increase image contrast, MRI relies on contrast agents (CAs).¹ Recently, many specific molecular imaging probes have been proposed to enable visualization of various biomarkers (peptides, enzyme activity, fluctuation in pH, pO₂ concentration of glucose or metal ions such as Ca(II), Zn(II), Cu(II), etc.).² Today, commercially available CAs are all Gd(III) complexes (Gd(III)-based CAs = GBCAs) formed with open-chain (linear) or macrocyclic ligands such as DTPA (diethylenetriamine-N,N,N',N'',N'''-pentaacetate) and DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or their derivatives. The lustrous history of MRI CAs seems to be undermined by safety concerns reported in the literature since the early 2000s. The emergence of a potentially fatal disease, Nephrogenic Systemic Fibrosis (NSF) in patients with poor renal function triggered by free Gd(III) ions released from CAs^{3,4} prompted a still growing interest to find non-Gd(III) alternatives. Later, from 2014, numerous reports have pointed out that multiple GBCA injections may result in Gd(III) accumulation even in patients with healthy kidney function and receiving exclusively macrocyclic GBCAs.^{5,6} These concerns have led to definite measures from regulatory agencies in Europe (<https://www.ema.europa.eu/en>). In 2017, the European Medicines Agency (EMA) suspended marketing authorizations for three out of the total five GBCAs based on a linear ligand and restricted the use of two other agents only for liver imaging complying with important diagnostic need. In parallel,

the Food and Drug Administration (FDA) issued a new class of warnings in relation with the use of GBCAs.

For several years, the paramagnetic Mn(II) has been in the forefront of contrast agent research as it is believed to be one of the most promising alternatives to Gd(III).¹ Naturally, when applied in high concentration, Mn(II) also displays toxicity.⁷ Mn(II) accumulation in the brain causes a neurological disorder known as manganism, expressing symptoms similar to Parkinson's disease.⁸ Therefore, Mn(II)-based agents must also be administered in the form of stable and inert complexes. Unfortunately, the thermodynamic stability and kinetic inertness of Mn(II) complexes are generally lower than that of Gd(III) or other transition metal counterparts, due to the smaller charge and lack of ligand-field stabilization energy (high-spin d^5 electron configuration). Mn(II) complexes formed with open-chain ligands are known to be kinetically labile; few exceptions involve the rigid CDTA and its derivatives (i.e. PyC3A) or PhDTA complexes (structure of the ligands mentioned in the text are included in Figure 1).⁹⁻¹¹ Being an essential metal ion, Mn(II) is efficiently eliminated from the living system, as it was recently demonstrated following injection of the acyclic [Mn(PyC3A)] chelate into rats.¹² On the other hand, for the majority of macrocyclic Mn(II) complexes, either low relaxivity (i.e. non aquated, but inert [Mn(NOTA)]⁻ or [Mn(DOTA)]²⁻) or limited inertness (bisaquated Mn(II) complexes of 15-membered macrocyclic ligands such as 15Py-aneN₅ or 15Py-aneN₅O₂) seem to limit potential *in vivo* application.¹³⁻¹⁵ A compromise between these seemingly contradictory requirements was recently found with Mn(II) complexes of 1,4-DO2A and its amide derivatives (1,4-DO2AM^{Me2}) by M. Botta and coworkers.^{16,17} These stable and inert chelates possess an average of 0.9 bound water molecule.

We propose here to consolidate efficient relaxation enhancement and kinetic inertness by using the pycen platform for Mn(II) complexation. Recent data on trisubstituted cyclododecanes have evidenced greater conditional stability for [Mn(PCTA)]⁻ than for [Mn(DOTA)]²⁻ (pH=7.4). The kinetic inertness of [Mn(PCTA)]⁻ was also found sufficiently high to allow for further ligand modification, such as reduction of ligand denticity to attain higher hydration number of the Mn(II) complex. Recently, we have proposed the PC2A-EA ligand as a pH responsive CA candidate which merges the advantageous Mn(II) binding properties of

NaCl; ^c determined by simultaneous fitting of pH-pot. and UV-Vis spectrophotometric data; ^d determined by UV-Vis spectrophotometry, ^e 25 °C, *I*=0.15 M NaCl; ^f Ref.²⁵, 25 °C, *I*=1.0 M KCl log *K*₅=1.29.

done for the Cu(PCTA) complex previously) may return erroneous stability constants.[ref] PCTA³⁻ forms a very stable Mn(II) complex and the removal of one metal binding function does not reduce stability (log *K*_{MnL}=16.83 and 17.09, for PCTA and PC2A, respectively). However, a noticeable decrease is observed upon the attachment of the electron-withdrawing biphenyl entity to PC2A (log *K*_{MnL}=14.86). The equilibrium model used for the analysis of the pH-potentiometric data has been confirmed with pH dependent ¹H relaxometry (Fig. S1), which also evidenced complete formation of the [Mn(PC2A-BP)] complex by pH=4.5. For the Cu(II) system, complex formation is quantitative already at pH=1.6, thus UV-Vis spectrophotometric titration in batch samples (Fig. S2) was used (22 samples in the [H⁺] concentration range of 0.003-1.030 M, see SI) to obtain the stability constant.

Stability constants alone do not allow comparing the capability of ligands with different basicity to sequester a given metal cation, as metal complexation and ligand protonation are competitive processes. p*M* values, defined as -log [M^{m+}]_{free}, give a more realistic picture about the conditional stability of the complexes at a given pH. The pMn values calculated at pH=7.4 and *c*_{Mn}=*c*_L=0.01 mM¹⁴ for [Mn(PC2A)] and [Mn(PC2A-BP)] are almost identical, while it is one order of magnitude higher for [Mn(PCTA)]⁻. Under these conditions, for [Mn(PC2A-BP)] less than 0.1% of total Mn(II) is non-chelated in equilibrium making it one of the most stable monoaquated Mn(II) complexes reported to date. Indeed, its p*M* value is very close to that of the highly stable, but non-hydrated [Mn(DOTA)²⁻] complex (pMn=9.02).¹³

The thermodynamic stability of the Zn(II) and Cu(II) complexes is orders of magnitude higher than that of the Mn(II) analogues (Table 1), in agreement with the Irving-Williams series. For this reason, the inertness of the Mn(II) complexes designed for MRI applications has to be particularly high to minimize Mn(II) release that could result from exchange reactions with endogenous ligands and metal ions. The inertness of [Mn(PC2A-BP)] was assessed by monitoring metal exchange reactions in the presence of high (10–40 fold) excess of Cu(II) ion, in the pH-range 3.3-5.0. Typically, Mn(II) and Gd(III) complexes follow analogous dissociation pathways (Scheme S1). These involve (i) spontaneous dissociation, (ii) proton-assisted pathways through the formation of protonated complexes or (iii) metal-assisted dissociation, occurring *via* direct attack of the exchanging metal ion on the protonated or deprotonated complex and the subsequent formation of a dinuclear intermediate (see SI for detailed description). Under pseudo-first-order conditions as applied in our study, the rate of the decomplexation can be drawn as in eqn. 1,

$$-\frac{d[\text{Mn}(\text{PC2A-BP})]_t}{dt} = k_{\text{obs}} [\text{Mn}(\text{PC2A-BP})]_t \quad \text{Eqn. 1.}$$

where *k*_{obs} is a pseudo-first-order rate constant and [Mn(PC2A-BP)]_t is the total concentration of the Mn(II) chelate.

The *k*_{obs} values increase with increasing H⁺ concentration, while remain independent of Cu(II) concentration, indicating the absence of a metal-assisted pathway (Figure 1). Taking into account the concentration of the protonated and deprotonated complexes ([Mn(PC2A-BP)]_t=[Mn(PC2A-BP)]+[Mn(HPC2A-BP)]) as well as the protonation constant of [Mn(PC2A-BP)] (*K*_H), the following rate equation can be derived (eqn. 2):

$$k_{\text{obs}} = \frac{k_0 + k_1[\text{H}^+]}{1 + K_{\text{H}}[\text{H}^+]} \quad \text{Eqn. 2.}$$




Figure 1. Dependence of the pseudo-first-order rate constants (*k*_{obs}) on the concentration of H⁺ and Cu(II) ions for the [Mn(PC2A-BP)] complex. The excess of the exchanging metal ion was ×10 (■), ×20 (◆), ×30 (▲) and ×40 (×) folds. The line corresponds to the best fit of the *k*_{obs} values to eqn. 2.

The fit of the *k*_{obs} values to equation 2 revealed that spontaneous dissociation is negligible (*k*₀ is zero). Thus the dissociation of the complex occurs exclusively through the proton-assisted pathway, with a rate constant of *k*₁ = 16.9±0.2 M⁻¹s⁻¹. The protonation constant of [Mn(PC2A-BP)] obtained is *K*_H=1350±110 M⁻¹, one order of magnitude lower than that for [Mn(PC2A)], reflecting the lower basicity of PC2A-BP. Nevertheless, the proton-assisted dissociation of [Mn(PC2A-BP)] is over 200 times faster than that of [Mn(PCTA)]⁻ (*k*₁^[Mn(PCTA)]=0.082 M⁻¹s⁻¹).¹³ In contrast to [Mn(PC2A)] and [Mn(PCTA)]⁻ the metal-assisted pathway is not active for [Mn(PC2A-BP)]. It is the consequence of the steric hindrance induced by the biphenyl moiety inhibiting any structural reorganization of the [Mn(PC2A-BP)] chelate that would be necessary to form a dinuclear intermediate. The lack of such metal-assisted pathway is responsible for the remarkable inertness of [Mn(PC2A-BP)]. At pH=7.4 and 25 °C, the dissociation half-life is *t*_{1/2}=286.2 hours for [Mn(PC2A-BP)], one order of magnitude higher than *t*_{1/2}=21.0 h for [Mn(PC2A)], though lower than *t*_{1/2}=5.9×10⁴ h for [Mn(PCTA)]. The *t*_{1/2} value calculated for [Mn(PC2A-BP)] is the half of that found for the [Mn(1,4-DO2AM^{Me2})]²⁺ complex, while the Mn(II) complex formed with a structurally related PC2A-EA ligand appears to be notably more inert (*t*_{1/2}=8×10³ h).^{17,18} Considering a 3–4-fold acceleration of the dissociation with the increase of temperature on going from 25 °C to 37 °C, one can estimate a half-life (*t*_{1/2}) of 72–95 hours for [Mn(PC2A-BP)] at physiological temperature which implies that substantial amount of the complex injected expected to be excreted intact (see SI for details) and the Mn(II) released *in vivo* from the complex is estimated to be below 1 mg (when applied at 0.3 mmol/kg in a 70 kg patient). Expectedly, the body can handle such low amounts of free Mn(II) without consequences on safety. These considerations are also in full accordance with the results of P. Caravan and co-workers who observed indeed very efficient elimination of the Mn(II) after injection of [Mn(PyC3A)]⁻ in rats.¹² Finally the stability test performed with the use of Seronorm solution have also confirmed the exceptional inertness of the complex (Fig S3).

The water-exchange rate, an important parameter that contributes to efficient relaxation enhancement, was determined by measuring

the ^{17}O transverse relaxation rates ($1/T_{2r}$) for an aqueous [Mn(PC2A-BP)] solution and a diamagnetic reference at different temperatures (9.4 T, Figure 2). The ^{17}O $1/T_{2r}$ data were analyzed by the Swift-Connick equations²⁶ assuming a simple exponential behavior of the electron spin relaxation (see SI for details). The hydration number was fixed to $q = 1$ (based on the proton relaxivity and the maximum ^{17}O $1/T_{2r}$ value allowing for an estimation of $q = 0.9 \pm 0.2$ according to Gale et al. Fig. S4).²⁷ The activation energy for the electron spin relaxation and the scalar coupling constant were set to $E = 1$ kJ/mol and $A_0/\hbar = 40 \times 10^6$ rad s^{-1} , respectively following literature recommendations.²⁸ The water exchange rate, $k_{\text{ex}}^{298} = (6.3 \pm 0.2) \times 10^7$ s^{-1} , its activation enthalpy, $\Delta H^\ddagger = 35.7 \pm 0.1$ kJ/mol, and the electron spin relaxation rate, $1/T_{1e}^{298} = (4.8 \pm 0.4) \times 10^7$ s^{-1} were calculated. The contribution of the electron spin relaxation term to the correlation time $1/\tau_c = k_{\text{ex}} + 1/T_{1e}$ is limited at high temperatures ($\sim 8\%$ at 348 K) which allows for an accurate determination of the water exchange rate. The k_{ex}^{298} value obtained for [Mn(PC2A-BP)] is slightly higher than value corresponding to the water exchange rate of [Mn(PC2A-EA)] ($k_{\text{ex}}^{298} = 4.0 \times 10^7$ s^{-1}),¹⁸ it is the half of that found for [Mn(PC2A)] ($k_{\text{ex}}^{298} = 15.2 \times 10^7$ s^{-1}) and more than 7 times lower than that of [Mn(EDTA)]²⁻ ($k_{\text{ex}}^{298} = 47.1 \times 10^7$ s^{-1}).¹⁵




Figure 2. Temperature dependence of the reduced ^{17}O transverse relaxation rates for [Mn(PC2A-BP)] at 9.4 T and pH 7.4. The line corresponds to the best fit of the data.

The difference in the water exchange rate of the [Mn(PC2A-BP)] and [Mn(PC2A)] complexes arises from the presence of the bi-phenyl pendant which can slow down the rearrangement of the coordination cavity during the water exchange process, similarly to triazacyclononane-diacetates (NO2A) bearing aromatic substituents.²⁹

In the presence of 0.7 mM HSA, the relaxivity of [Mn(PC2A-BP)] undergoes a six fold increase (23.5 vs. 3.8 $\text{mM}^{-1}\text{s}^{-1}$ in the absence of HSA; 37 °C, 0.49 T)^{22,23}, indicating a strong interaction between the [Mn(PC2A-BP)] complex and the protein ($\log K_{\text{aff}} = 3.4 \pm 0.1$ and $r_{1b} = 35.7 \pm 2.5$ $\text{mM}^{-1}\text{s}^{-1}$, see ESI for more relaxivity data, Fig S5-S8). The r_{1b} value is lower than those observed for the majority of EDTA-like Mn(II) chelates by M. Botta and coworkers, while other EDTA-based HSA targeting structures showed similar relaxivity and considerably higher (by an order of magnitude) affinity constant (Table 2).^{22,30} Similar relaxivity values (r_{1p}^b) and binding constants were observed, however, for Mn(II) chelates formed with DO2A-bis(amide) or amphiphilic DO2A derivative ligands (Table 2).³¹

Table 2. Comparison of relaxivities (0.49 T MHz; 298 K) and HSA binding affinities of some macrocyclic ligand based Mn(II) complexes.

	\log ($n \times K_{\text{aff}}$)	r_{1p} ($\text{mM}^{-1}\text{s}^{-1}$)	r_{1p}^b ($\text{mM}^{-1}\text{s}^{-1}$)
[Mn(PC2A-BP)]	3.4±0.1	4.96±0.5	35.7±2.5
[Mn(BzDO2AM ^{Me2}) ²⁺ , a	3.59	3.8	18.5
[Mn(DO2AM ^{Bz}) ²⁺ , a	3.08	3.5	27.4
[Mn(DD-DO2A)] ^b	4.36	12.6	29.5
[Mn(DH-DO2A)] ^b	4.00	15.3	27.2

^a ref. 31; ^b ref. 32 *Dalton Trans.*, 2018, **47**, 10660-10670.

The efficacy of the [Mn(PC2A-BP)] complex as an HSA targeting probe was evaluated in MRI experiments at 3 T magnetic field strength by using phantoms with 0.20 mM complex in serum or in the presence of 0.7 mM HSA (Fig S9). Analysis of the MR images indicate that the signal intensity changes notably on going from [Mn(CDTA)]²⁻ to [Mn(PC2A-BP)] alone, but more pronounced brightening of T_1 images is observed when the HSA (or other proteins present in the serum) appears in the sample.

HSA is an important protein target for angiographic imaging and the potential of [Mn(PC2A-BP)] for the visualization of the vascular system has been demonstrated in an angiographic MRI study in Swiss mice.^{19,32} MR dynamic contrast enhanced imaging (DCE) has been performed in Swiss mice to follow the biodistribution of [Mn(PC2A-BP)]. After the injection of the complex, there is an immediate increase in signal intensity in the kidney, followed by a decrease. This indicates that a part of the contrast agent is excreted via the kidneys. This elimination phase is quicker than that for the Dotarem, a GBCA used in clinical practice ([Gd(DOTA)]Meg). In parallel, intensity also increases in the liver and remains constant for a period of 15 minutes (Fig. S10). This is likely the cumulative effect of some hepatocellular uptake and the presence of the agent in the blood vessels of the highly vascularized liver. The signal intensity increase in the liver is less pronounced than that in the kidney medulla. Vascular cerebral blood flow was measured by Magnetic Resonance Angiography (MRA) using a Fast Low Angle Shot (FLASH) sequence at an injected dose of 25 $\mu\text{mol}/\text{kg}$ of [Mn(PC2A-BP)], which is 4 times smaller than the standard dose of the Gd(III) based MRI CAs used for clinical experiments. [Mn(PC2A-BP)] provided a substantial increase in blood signal that allowed the visualization of brain vascularization in more details than without the contrast agent. It highlighted micro-vascularization which was invisible without injecting the chelate as demonstrated in Figure 3 which represents pre- and post-injection angiographic MR images as well as the signal intensity difference between the two. The increase in blood signal intensity was retained even 30 minutes after the injection, and could be quantified as +26% at this time point with respect to the signal intensity prior to injection. MRA can be typically performed without the use of contrast agents or with extracellular fluid agents like Magnevist ([Gd(DTPA)]Meg₂) and Dotarem by imaging few seconds after injection during the first pass of the agent through the vasculature.¹⁹ Nevertheless, a substantial improvement in highlighting the microvessels, otherwise invisible, and the extension of the time window available for imaging can be beneficial in certain cases, such as in characterizing the tumor vascularization.




Figure 3. Angiographic MR images of a Swiss mouse brain acquired (a) before and (b) 30 min after i.v. administration of [Mn(PC2A-BP)] at a dose of 25 $\mu\text{mol/kg}$, using a FLASH sequence (FOV = 1.83*1.83 cm, x 14 mm², matrix = 256 x 256, TR/TE = 30/5 ms, 51 axial slices 0.2 mm thickness, NA = 4, experimental time = 13 min). (c) Signal intensity increase observed at 30 min post-injection with respect to the pre-injection angiographic MR image.

Conclusion

In conclusion, we have demonstrated that the PC2A platform and in particular the PC2A-BP is a promising chelator of Mn(II). The chemical design involving a bulky substituent on the macrocycle nitrogen prevents metal-assisted dissociation pathways and induces remarkable inertness ($t_{1/2}$ =286.2 hours at 25 °C). This, combined with an excellent thermodynamic stability ($\log K_{[\text{Mn}(\text{PC2A-BP})]}=14.86$, $\text{pMn}=8.3$), minimizes potential *in vivo* metal release (based on serum stability studies it is estimated below 0.05 %). The high relaxivity observed in the presence of HSA ($r_{1p} = 23.5 \text{ mM}^{-1}\text{s}^{-1}$, 20 MHz, 37 °C) allows to considerably lower the injected dose of the CA (25 $\mu\text{mol/kg}$) and yet to obtain excellent visualization of the mouse brain vasculature.

Experimental Section

General Remarks. Starting commercial reagents/solvents were purchased from Sigma-Aldrich (St. Louis, MO, USA), Tokyo Chemical Industry (Tokyo, Japan) and Fluorochem (Hadfield, Glossop, UK) and were used without further purification unless otherwise stated. Deionized Milli-Q® water was used for the preparation of all aqueous solutions (equilibrium/kinetic/relaxometric studies). ¹H NMR spectra were recorded on a Bruker Avance 360 or 400 MHz spectrometer (chemical shifts are given as δ values with reference to tetramethylsilane and coupling constants are reported in Hz). Mass spectroscopic characterization of the product was performed in the Laboratory of Instrumental Analysis, Department of Organic Chemistry of the University of Debrecen equipped with Thermo Accela 600 UPLC system coupled with LTQ-XL mass spectrometer. Prior to its use in the analytical experiments, the final product was purified by preparative high-pressure liquid chromatography (HPLC). Analytical HPLC was performed with the a Waters Alliance 2690 HPLC (Waters Inc., USA) system equipped with a Luna C18(2) 150 mm \times 4.6 mm, 100Å, 5 μm column (Phenomenex Inc., USA), at 25 °C temperature, with a flow rate of 1.00 mL/min. Preparative separations were performed using HPLC technique (YL9100 HPLC, Korea) equipped with a Luna C18(2) column (250 mm \times 21.2 mm, 100Å, 5 μm , Phenomenex Inc. USA). The solvent flow rate in this case was 25.00 mL/min using gradient elution as follows: eluent A (5 mM TFA in water) and B (ACN); gradient: 15% B to 40% B in 7.50 min. The purity of the product was >99.8 % determined by reverse-phase HPLC with UV-vis detection at 210 and 260 nm (Fig. S12). Equilibrium studies were performed by pH-potentiometry, with complementary methods applied for Cu(II) (UV-vis) and Mn(II) (¹H-relaxometry) complexes (see ESI for detailed description). Kinetic studies were performed either by following metal exchange reactions with Cu(II) (UV-vis spectrophotometry) or changes in T_2 relaxation times in the presence

of large Zn(II) excess as a function of time as proposed by P. Caravan et. al.¹¹ To assess the water exchange rate of the Mn(II) complex, ¹⁷O-NMR studies were performed on a Bruker Avance 400 MHz spectrometer. Relaxivity was determined on a Bruker Minispec MQ20 (pH-dependence) and MQ60 (dissociation kinetic study) relaxometers. Imaging studies were performed in phantoms (Philips Achieva 3 T system) and in female Swiss mice (RjOrl:SWISS, Janvier Labs) using small animal imaging (70/16 Bruker Pharmascan, Wissembourg, France) MRI system. Animal experiments were performed at Centre de Biophysique Moléculaire (CBM CNRS UPR431) in Orléans, France in accordance to national and European laws and regulations. The project was authorized by the Ministère de l'enseignement supérieur de la recherche et de l'innovation with the number 20366. We conform to the Council Directive of 24 November 1986 on The Approximation Of Laws, Regulations And Administrative Provisions Of The Member States Regarding The Protection Of Animals Used For Experimental And Other Scientific Purposes (86/609/Eec and 2010/63/EU). Detailed descriptions of these methods and conditions are included in SI.

Synthesis of the PC2A-BP ligand. The PC2A-BP ligand was prepared by alkylating the bis-methylcyanide-pyclen precursor (3,9-bis(methylenitrile)-3,6,9,15-tetraazabicyclo[9.3.1]pentadecan-11,13-triene 1) prepared by following the procedure of Kim et al.²⁴ with the commercially available 4-phenylbenzyl chloride in the presence of Hüning's base as follows: 150 mg (0,528 mmol) of bis-methylcyanide-pyclen (1) was dissolved in 5 mL of dry acetonitrile under Ar protected atmosphere and 0.185 ml (1.06 mmol) of Hüning's base (DIPEA) as well as 45 mg (0,268 mmol) of KI was added to the solution. The reaction mixture was heated to 60 °C by using an oil bath and 0.118 g (0.580 mmol) of 4-phenylbenzyl chloride dissolved in 5 mL of dry acetonitrile was added to the suspension dropwise during 3 hours. The reaction mixture was stirred at the given temperature for 40 hours, filtered and the filtrate evaporated to dryness under reduced pressure. The oily residue was redissolved in 10 mL of 12 M HCl and the solution was refluxed for 25 h at 110 °C. The reaction mixture was then evaporated to dryness under reduced pressure and the residue was redissolved in 4 mL of double distilled water. Separation via preparative HPLC (Fig. S11) yielded PC2A-BP as off white solid upon freeze-drying the combined fractions containing the product. Yield 144 mg (81%).

¹H-NMR (Fig. S12): (360,13 MHz, D₂O) δ = 3.16 (m 4H, >N-CH₂-CH₂-) 3.38 (m 4H, >N-CH₂-CH₂-) 3.74 (s 4H, >N-CH₂-COOH) 4.26 (s 2H, >N-CH₂-C₁₂H₉) 4.52 (s 4H, >N-CH₂-Py) 7.44 (t 1H, -CH-CH-CH- (C₁₂H₉)) 7.53 (m 2H, -CH-CH-CH- (C₁₂H₉)) 7.62 (d 4H, -CH-CH- (C₁₂H₉)) 7.72 (m 2H, -CH-CH-CH- (Py)) 7.73 (m 2H, -CH-C-CH- (C₁₂H₉)) 8.19 (t 1H, -CH-CH-CH- (Py)).

¹³C-NMR (Fig. S12): (100 MHz, D₂O) δ = 51.6 (4C, 2p >N-CH₂-CH₂-) 56.6 (4C, 2p >N-CH₂-COOH and 2p >N-CH₂-Py) 58.1 (1C, >N-CH₂-C₁₂H₉) 123.8 (2C, -CH-CH-CH- (Py)) 127.1 (1C, -CH-CH-CH- (C₁₂H₉)) 127.8 (4C, 2p -CH-C-CH- (C₁₂H₉)) 128.3 (1C, -CH-CH-CH- (Py)) 129.3 (2C, -CH-CH-CH- (C₁₂H₉)) 131.8 (2C, -CH-C(CH₂)-CH- (C₁₂H₉)) 139.7 (1C, -CH-C(CH₂)-CH- (C₁₂H₉)) 143.6 (2C, 2p -CH-C-CH- (C₁₂H₉)) 151.5 (2C, 2p -CH₂-C-N_{py}) 163.1 (2C, 2p -COOH).

MS (ESI) m/z 489,25(M+H)⁺ 100%; 542,17(M+Na)⁺ 15%.

Corresponding Author

eva.jakabtoth@cnrs.fr
gyula.tircso@science.unideb.hu

Notes

The authors declare no competing financial interests.

ACKNOWLEDGMENT

The authors acknowledge financial support of the Hungarian National Research, Development and Innovation Office (NKFIH K-120224 project), the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (G. T. and F. K. K.), the COST Action CA15209 European Network on NMR Relaxometry and the French National Research Agency (ANR, MANGA CE18-0008-01). The research was also supported in a part by the EU and co-financed by the European Regional Development Fund under the projects GINOP-2.3.2-15-2016-00008 and GINOP-2.3.3-15-2016-00004 and by the ÚNKP-18-4 New National Excellence Program (Gy. T. and F. K. K.) of the Ministry of Human Capacities.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website. A scheme describing the dissociation mechanism of the Mn(II) chelate; determination of relaxivity at 0.49 and 7 T, pH-profile of the relaxivity; determination of the binding constant for the HSA adduct, determination of the number of bound water molecules in Mn(II) chelate; NMRD profiles in the absence and presence of HSA; results of phantom and in vivo (DCE) MRI studies, additional experimental details (^1H - and ^{13}C -NMR spectra, HPLC trace) and results of in vitro/in vivo MRI studies, equations used during the fitting of ^1H - and ^{17}O -relaxometric data (PDF).

ABBREVIATIONS USED

DTPA, diethylenetriamine-N,N,N',N'',N'''-pentaacetate; DOTA, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; CA, Contrast Agent; GBCA, Gd-Based Contrast Agents; NSF, Nephrogenic Systemic Fibrosis; EMA, European Medicines Agency; $1/T_{2r}$, transverse relaxation rate; MRA Magnetic Resonance Angiography; DCE imaging, dynamic contrast enhanced imaging;

REFERENCES

- (1) Doan, B.-T.; Meme, S.; Beloeil, J.-C. General Principles of MRI. In *The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging*; Merbach, A., Helm, L., Tóth, É., Eds.; John Wiley & Sons Ltd: Chichester, UK, 2013; pp 1–24.
- (2) Parrott, D.; Fernando, W. S.; Martins, A. F. Smart MRI Agents for Detecting Extracellular Events In Vivo: Progress and Challenges. *Inorganics* **2019**, *7* (2), 18.
- (3) Grobner, T. Gadolinium – a Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis? *Nephrology Dialysis Transplantation* **2006**, *21* (4), 1104–1108.
- (4) Darrach, T. H.; Prutsman-Pfeiffer, J. J.; Poreda, R. J.; Ellen Campbell, M.; Hauschka, P. V.; Hannigan, R. E. Incorporation of Excess Gadolinium into Human Bone from Medical Contrast Agents. *Metallomics* **2009**, *1* (6), 479.
- (5) Kanal, E.; Tweedle, M. F. Residual or Retained Gadolinium: Practical Implications for Radiologists and Our Patients. *Radiology* **2015**, *275* (3), 630–634.
- (6) Kanda, T.; Fukusato, T.; Matsuda, M.; Toyoda, K.; Oba, H.; Kotoku, J.; Haruyama, T.; Kitajima, K.; Furui, S. Gadolinium-Based Contrast Agent Accumulates in the Brain Even in Subjects without Severe Renal Dysfunction: Evaluation of Autopsy Brain Specimens with Inductively Coupled Plasma Mass Spectroscopy. *Radiology* **2015**, *276* (1), 228–232.
- (7) Pan, D.; Schmieder, A. H.; Wickline, S. A.; Lanza, G. M. Manganese-Based MRI Contrast Agents: Past, Present, and Future. *Tetrahedron* **2011**, *67* (44), 8431–8444.
- (8) Cersosimo, M. G.; Koller, W. C. The Diagnosis of Manganese-Induced Parkinsonism. *NeuroToxicology* **2006**, *27* (3), 340–346.
- (9) Pota, K.; Garda, Z.; Kálmán, F. K.; Barriada, J. L.; Esteban-Gómez, D.; Platas-Iglesias, C.; Tóth, I.; Brücher, E.; Tirscsó, G. Taking the next Step toward Inert Mn^{2+} Complexes of Open-Chain Ligands: The Case of the Rigid PhDTA Ligand. *New Journal of Chemistry* **2018**, *42* (10), 8001–8011.
- (10) Kálmán, F. K.; Tirscsó, G. Kinetic Inertness of the Mn^{2+} Complexes Formed with AAZTA and Some Open-Chain EDTA Derivatives. *Inorganic Chemistry* **2012**, *51* (19), 10065–10067.
- (11) Gale, E. M.; Atanasova, I. P.; Blasi, F.; Ay, I.; Caravan, P. A Manganese Alternative to Gadolinium for MRI Contrast. *Journal of the American Chemical Society* **2015**, *137* (49), 15548–15557.
- (12) Erstad, D. J.; Ramsay, I. A.; Jordan, V. C.; Sojoodi, M.; Fuchs, B. C.; Tanabe, K. K.; Caravan, P.; Gale, E. M. Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A. *Investigative Radiology* **2019**, *54* (11), 697–703.
- (13) Garda, Z.; Molnár, E.; Kálmán, F. K.; Botár, R.; Nagy, V.; Baranyai, Z.; Brücher, E.; Kovács, Z.; Tóth, I.; Tirscsó, G. Effect of the Nature of Donor Atoms on the Thermodynamic, Kinetic and Relaxation Properties of Mn(II) Complexes Formed With Some Trisubstituted 12-Membered Macrocyclic Ligands. *Frontiers in Chemistry* **2018**, *6*, 232.
- (14) Drahoš, B.; Kotek, J.; Hermann, P.; Lukeš, I.; Tóth, É. Mn^{2+} Complexes with Pyridine-Containing 15-Membered Macrocycles: Thermodynamic, Kinetic, Crystallographic, and $^1\text{H}/^{17}\text{O}$ Relaxation Studies. *Inorganic Chemistry* **2010**, *49* (7), 3224–3238.
- (15) Drahoš, B.; Lukeš, I.; Tóth, É. Manganese(II) Complexes as Potential Contrast Agents for MRI. *European Journal of Inorganic Chemistry* **2012**, *2012* (12), 1975–1986.
- (16) Garda, Z.; Forgács, A.; Do, Q. N.; Kálmán, F. K.; Timári, S.; Baranyai, Z.; Tei, L.; Tóth, I.; Kovács, Z.; Tirscsó, G. Physico-Chemical Properties of Mn^{II} Complexes Formed with *Cis*- and *Trans*-DO2A: Thermodynamic, Electrochemical and Kinetic Studies. *Journal of Inorganic Biochemistry* **2016**, *163*, 206–213.
- (17) Forgács, A.; Tei, L.; Baranyai, Z.; Tóth, I.; Zékány, L.; Botta, M. A Bisamide Derivative of $[\text{Mn}(1,4\text{-DO2A})]$ Solution Thermodynamic, Kinetic, and NMR Relaxometric Studies. *European Journal of Inorganic Chemistry* **2016**, *2016* (8), 1165–1174.
- (18) Botár, R.; Molnár, E.; Trencsényi, G.; Kiss, J.; Kálmán, F. K.; Tirscsó, G. Stable and Inert Mn(II)-Based and pH-Responsive Contrast Agents. *Journal of the American Chemical Society* **2020**, *142* (4), 1662–1666.
- (19) Gale, E. M.; Wey, H.-Y.; Ramsay, I.; Yen, Y.-F.; Sosnovik, D. E.; Caravan, P. A Manganese-Based Alternative to Gadolinium: Contrast-Enhanced MR Angiography, Excretion, Pharmacokinetics, and Metabolism. *Radiology* **2018**, *286* (3), 865–872.
- (20) Wang, J.; Wang, H.; Ramsay, I. A.; Erstad, D. J.; Fuchs, B. C.; Tanabe, K. K.; Caravan, P.; Gale, E. M. Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure–Activity Relationships and Lead Candidate Evaluation. *Journal of Medicinal Chemistry* **2018**, *61* (19), 8811–8824.

- (21) Islam, Md. K.; Kim, S.; Kim, H.-K.; Park, S.; Lee, G.-H.; Kang, H. J.; Jung, J.-C.; Park, J.-S.; Kim, T.-J.; Chang, Y. Manganese Complex of Ethylenediaminetetraacetic Acid (EDTA)–Benzothiazole Aniline (BTA) Conjugate as a Potential Liver-Targeting MRI Contrast Agent. *Journal of Medicinal Chemistry* **2017**, *60* (7), 2993–3001.
- (22) Rolla, G.; De Biasio, V.; Giovenzana, G. B.; Botta, M.; Tei, L. Supramolecular Assemblies Based on Amphiphilic Mn^{2+} -Complexes as High Relaxivity MRI Probes. *Dalton Transactions* **2018**, *47* (31), 10660–10670.
- (23) Troughton, J. S.; Greenfield, M. T.; Greenwood, J. M.; Dumas, S.; Wiethoff, A. J.; Wang, J.; Spiller, M.; McMurry, T. J.; Caravan, P. Synthesis and Evaluation of a High Relaxivity Manganese(II)-Based MRI Contrast Agent. *Inorganic Chemistry* **2004**, *43* (20), 6313–6323.
- (24) Kim, W. D.; Hrnčir, D. C.; Kiefer, G. E.; Sherry, A. D. Synthesis, Crystal Structure, and Potentiometry of Pyridine-Containing Tetraaza Macrocyclic Ligands with Acetate Pendant Arms. *Inorganic Chemistry* **1995**, *34* (8), 2225–2232.
- (25) Tircs6, G.; Kovács, Z.; Sherry, A. D. Equilibrium and Formation/Dissociation Kinetics of Some Ln^{III} PCTA Complexes. *Inorganic Chemistry* **2006**, *45* (23), 9269–9280.
- (26) Swift, T. J.; Connick, R. E. Erratum: NMR-Relaxation Mechanisms of ^{17}O in Aqueous Solutions of Paramagnetic Cations and the Lifetime of Water Molecules in the First Coordination Sphere. *The Journal of Chemical Physics* **1964**, *41* 2553-2554.
- (27) Gale, E. M.; Zhu, J.; Caravan, P. Direct Measurement of the Mn(II) Hydration State in Metal Complexes and Metalloproteins through ^{17}O NMR Line Widths. *Journal of the American Chemical Society* **2013**, *135* (49), 18600–18608.
- (28) Esteban-Gómez, D.; Cassino, C.; Botta, M.; Platas-Iglesias, C. ^{17}O and 1H Relaxometric and DFT Study of Hyperfine Coupling Constants in $[Mn(H_2O)_6]^{2+}$. *RSC Advances* **2014**, *4* (14), 7094.
- (29) Pujales-Paradela, R.; Carniato, F.; Esteban-Gómez, D.; Botta, M.; Platas-Iglesias, C. Controlling Water Exchange Rates in Potential Mn^{2+} -Based MRI Agents Derived from NO_2A^{2-} . *Dalton Transactions* **2019**, *48* (12), 3962–3972.
- (30) Baroni, S.; Colombo Serra, S.; Fringuello Mingo, A.; Lux, G.; Giovenzana, G. B.; Lattuada, L. Synthesis and Relaxometric Characterization of a New Mn(II)-EDTA-Deoxycholic Acid Conjugate Complex as a Potential MRI Blood Pool Agent. *Chemistry Select* **2016**, *1* (8), 1607–1612.
- (31) Forgács, A.; Tei, L.; Baranyai, Z.; Esteban-Gómez, D.; Platas-Iglesias, C.; Botta, M. Optimising the Relaxivities of Mn^{2+} Complexes by Targeting Human Serum Albumin (HSA). *Dalton Transactions* **2017**, *46* (26), 8494–8504.
- (32) Gale, E. M.; Caravan, P. Gadolinium-Free Contrast Agents for Magnetic Resonance Imaging of the Central Nervous System. *ACS Chemical Neuroscience* **2018**, *9* (3), 395–397.

SYNOPSIS TOC

